Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05755269 · ClinicalTrials.gov registry record
Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women
A clinical trial of Breast Carcinoma and Breast Lobular Carcinoma In Situ, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- 50
- Enrollment target
- 1
- Study location
NCT05755269 is a study of Breast Carcinoma and Breast Lobular Carcinoma In Situ that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 50 participants, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05755269, a study of Breast Carcinoma and Breast Lobular Carcinoma In Situ, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This study evaluates whether adding a polygenic risk score evaluation to standard breast cancer risk assessment tools helps African American and Hispanic women make more informed decisions about accepting additional breast cancer screening and prevention strategies. Traditional breast cancer risk assessments rely mostly on the presence of standard clinical risk factors including family history, reproductive history, and mammographic breast density. This information can be combined with validated risk estimation models to provide a measure of a patient's 10 year and lifetime risk for breast cancer. A polygenic risk score helps to estimate breast cancer risk in a more individualized way by evaluating a patient's genetics. Adding a polygenic risk score evaluation to traditional screening techniques may help minority women make more informed decisions about screening and prevention strategies for breast cancer.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Survey Administration
- PROCEDURE Genotyping
Study Locations (1)
Florida
- Mayo Clinic in Florida - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2033-01-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05755269
The ClinicalTrials.gov registry entry for NCT05755269 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 770-participant average among 106 other Breast Carcinoma trials with a reported enrollment target (94% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Breast Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Biospecimen Collection is the first listed.
NCT05755269 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05755269 about?
NCT05755269 is a clinical study titled "Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women". This study evaluates whether adding a polygenic risk score evaluation to standard breast cancer risk assessment tools helps African American and Hispanic women make more informed decisions about accepting additional breast cancer screening and prevention strategies. Traditional breast cancer risk as...
What is the current status of trial NCT05755269?
This trial is currently recruiting. The enrollment target is 50 participants. The study started on 2023-03-14. Estimated completion is 2033-01-15.
What conditions does trial NCT05755269 study?
This clinical trial studies the following conditions: Breast Carcinoma, Breast Lobular Carcinoma In Situ, Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia.
What interventions are being tested in trial NCT05755269?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Survey Administration (OTHER), Genotyping (PROCEDURE).
Who is sponsoring clinical trial NCT05755269?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05755269 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surviving Daily Life
RECRUITING
-
Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
RECRUITING
-
Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer
RECRUITING · Phase 2
-
Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer
RECRUITING · Phase 2
-
Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer
RECRUITING
-
Impact of Dietary Inflammatory Potential on Breast Cancer Risk
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.